抗逆转录病毒治疗对赞比亚HIV感染成人肝纤维化的影响:合并与不合并HBV感染
赞比亚463例HIV感染成人(61例合并HBV)启动含替诺福韦方案抗逆转录病毒治疗(ART),1年后瞬时弹性成像肝硬度中位变化-0.70 kPa(95%CI -3.0至+1.7),合并与不合并HBV者相似;
要点
- 肝硬度中位变化-0.70 kPa(95%CI -3.0至+1.7),合并与不合并HBV者相似。
核心结论
- HIV感染成人启动ART后提示显著纤维化/肝硬化的肝硬度升高比例下降,且不取决于HBV合并状态。
- 合并HBV感染者1年时更可能出现显著纤维化/肝硬化。
研究设计与样本
- 赞比亚HIV感染成人队列,分析463例(61例合并HBV),中位年龄35岁,53.7%为女性,基线中位CD4+计数240 cells/mm3。
- 以瞬时弹性成像肝硬度测量(LSM,kPa)在ART启动时分类为无/轻微纤维化(相当于Metavir F0-F1)、显著纤维化(F2-F3)和肝硬化(F4),ART 1年后重复检测。
- 按基线HBsAg阳性分层描述LSM变化和纤维化类别升降比例,用多变量logistic回归评估ART 1年时显著纤维化/肝硬化的相关因素。
主要发现
- 97.6%患者接受含替诺福韦二吡呋酯的ART,符合国家推荐一线治疗。
- LSM中位变化为-0.70 kPa(95%CI -3.0至+1.7),合并与不合并HBV感染相似。
临床怎么用
- 对HIV感染成人启动含替诺福韦ART后,可预期肝硬度提示的显著纤维化/肝硬化比例下降。
- 合并HBV感染、年龄较大和男性患者1年时显著纤维化/肝硬化风险更高,应加强纤维化监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated changes in hepatic fibrosis, based on transient elastography (TE), among human immunodeficiency virus (HIV)-infected patients with and without hepatitis B virus (HBV) coinfection on antiretroviral therapy (ART) in Zambia. METHODS: Patients' liver stiffness measurements (LSM; kiloPascals [kPa]) at ART initiation were categorized as no or minimal fibrosis (equivalent to Metavir F0-F1), significant fibrosis (F2-F3), and cirrhosis (F4). TE was repeated following 1 year of ART. Stratified by HBV coinfection status (hepatitis B surface antigen positive at baseline), we described LSM change and the proportion with an increase/decrease in fibrosis category. Using multivariable logistic regression, we assessed correlates of significant fibrosis/cirrhosis at 1 year on ART. RESULTS: Among 463 patients analyzed (61 with HBV coinfection), median age was 35 years, 53.7% were women, and median baseline CD4+ count was 240 cells/mm3. Nearly all (97.6%) patients received tenofovir disoproxil fumarate-containing ART, in line with nationally recommended first-line treatment. The median LSM change was -0.70 kPa (95% confidence interval, -3.0 to +1.7) and was similar with and without HBV coinfection. Significant fibrosis/cirrhosis decreased in frequency from 14.0% to 6.7% (P < .001). Increased age, male sex, and HBV coinfection predicted significant fibrosis/cirrhosis at 1 year (all P < .05). CONCLUSION: The percentage of HIV-infected Zambian adults with elevated liver stiffness suggestive of significant fibrosis/cirrhosis decreased following ART initiation-regardless of HBV status. This suggests that HIV infection plays a role in liver inflammation. HBV-coinfected patients were more likely to have significant fibrosis/cirrhosis at 1 year on ART. CLINICAL TRIALS REGISTRATION: NCT02060162.
引用
- Vinikoor MJ, Sinkala E, Chilengi R, et al. Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia. Clin Infect Dis. 2017. PMID: 28158504. doi:10.1093/cid/cix122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。